Cigna Group
CI
295.44
+0.25
+0.08%
Cigna Group
US · CI
#312 by market cap
Listed 1970
295.44
+0.25
+0.08%
Live - 5344 symbols - heartbeat 207s ago
· 2026-11-03 20:02
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.67, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +11.24% YoY
Margins
- Gross margin
- 8.95%
- Operating margin
- 2.98%
- Net margin
- 2.18%
Key ratios & quality
- Enterprise valuei
- 100.88B
- Altman Z-Scorei
- 2.67
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 48.65B | 153.57B | 160.40B | 174.07B | 180.52B | 195.27B | 247.12B | 274.90B |
| Gross profit | 14.85B | 23.69B | 22.96B | 21.40B | 22.35B | 24.01B | 24.99B | 24.51B |
| Selling & admin expenses | 11.93B | 14.05B | 14.07B | 13.01B | 13.17B | 14.82B | 14.84B | 14.62B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 2.68B | 6.69B | 6.91B | 6.39B | 7.30B | 7.37B | 8.44B | 8.15B |
| Pretax profit | 3.58B | 6.57B | 10.87B | 6.79B | 8.40B | 5.51B | 5.27B | 7.78B |
| Tax | 935.00M | 1.45B | 2.38B | 1.37B | 1.62B | 141.00M | 1.49B | 1.49B |
| Net profit | 2.65B | 5.12B | 8.49B | 5.42B | 6.78B | 5.37B | 3.78B | 6.29B |
| Basic EPS | 11 | 14 | 23 | 16 | 22 | 18 | 12 | 22 |
| Diluted EPS | 10.54 | 13.44 | 22.96 | 15.75 | 21.41 | 17.39 | 12.12 | 22.18 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 65.50B | 67.18B | 69.75B | 72.47B | 68.49B | 71.67B |
| Gross profit | 6.37B | 5.93B | 6.14B | 6.08B | 6.27B | 6.26B |
| Selling & admin expenses | 4.21B | 3.43B | 3.36B | 3.61B | 3.72B | 3.47B |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 1.73B | 2.07B | 2.35B | 2.01B | 2.16B | 2.40B |
| Pretax profit | 1.65B | 2.02B | 2.30B | 1.82B | 2.27B | 2.26B |
| Tax | 239.00M | 389.00M | 322.00M | 543.00M | 409.00M | 382.00M |
| Net profit | 1.41B | 1.63B | 1.97B | 1.27B | 1.86B | 1.88B |
| Basic EPS | 5 | 6 | 7 | 5 | 6 | 6 |
| Diluted EPS | 4.85 | 5.71 | 6.98 | 4.64 | 6.26 | 6.29 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 20.43B | 29.85B | 27.80B | 36.13B | 30.12B | 37.35B | 48.87B | 47.81B |
| Cash & ST investments | 5.87B | 5.56B | 11.50B | 5.96B | 6.76B | 8.57B | 8.22B | 8.65B |
| Inventory | 2.82B | 2.66B | 3.17B | 3.72B | 4.78B | 5.65B | 6.69B | 7.34B |
| Total assets | 153.23B | 155.77B | 155.45B | 154.89B | 143.89B | 152.76B | 155.88B | 157.92B |
| Total current liabilities | 31.90B | 40.14B | 36.02B | 43.57B | 41.23B | 48.72B | 57.98B | 56.34B |
| Short-term debt | 2.96B | 5.51B | 3.37B | 2.55B | 2.99B | 2.78B | 3.04B | 592.00M |
| Long-term debt | 39.52B | 31.89B | 29.55B | 31.13B | 28.10B | 28.16B | 28.94B | 30.87B |
| Total liabilities | 112,154,000,000.00 | 110,395,000,000.00 | 105,065,000,000.00 | 107,705,000,000.00 | 99,131,000,000.00 | 106,410,000,000.00 | 114,638,000,000.00 | 116,045,000,000.00 |
| Total equity | 41.07B | 45.38B | 50.39B | 47.18B | 44.75B | 46.35B | 41.24B | 41.87B |
| Retained earnings | 15.09B | 20.16B | 28.58B | 32.59B | 37.94B | 41.65B | 43.52B | 47.87B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 43.56B | 44.72B | 46.74B | 47.81B | 43.03B | 46.99B |
| Cash & ST investments | 9.00B | 5.04B | 6.81B | 8.65B | 7.80B | 7.17B |
| Inventory | 5.18B | 5.97B | 5.63B | 7.34B | 5.83B | 5.85B |
| Total assets | 150.66B | 151.65B | 157.92B | 157.92B | 153.27B | 157.08B |
| Total current liabilities | 55.75B | 56.78B | 56.45B | 56.34B | 52.61B | 55.56B |
| Short-term debt | 3.99B | 4.29B | 3.09B | 592.00M | 1.53B | 2.79B |
| Long-term debt | 26.46B | 26.48B | 30.95B | 30.87B | 29.37B | 29.09B |
| Total liabilities | 110,244,000,000.00 | 111,221,000,000.00 | 115,905,000,000.00 | 116,045,000,000.00 | 110,824,000,000.00 | 114,172,000,000.00 |
| Total equity | 40.41B | 40.43B | 42.01B | 41.87B | 42.44B | 42.91B |
| Retained earnings | 44.43B | 45.56B | 47.03B | 47.87B | 49.11B | 50.36B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 3.77B | 9.49B | 10.35B | 7.19B | 8.66B | 11.81B | 10.36B | 9.60B |
| Depreciation & amortization | 695.00M | 3.65B | 2.80B | 2.92B | 2.94B | 3.04B | 2.78B | 2.78B |
| Free cash flow | 3.24B | 8.44B | 9.26B | 6.04B | 7.36B | 10.24B | 8.96B | 8.39B |
| Dividends paid | -- | -15.00M | -15.00M | -1.34B | -1.38B | -1.45B | -1.57B | -1.61B |
| Stock buybacks / issuance | -274.00M | -1.76B | -3.67B | -7.42B | -7.22B | -2.10B | -6.73B | -3.42B |
| Ending cash balance | 3.86B | 5.41B | 10.25B | 5.55B | 5.98B | 8.34B | 8.93B | 7.74B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 1.92B | -1.89B | 3.42B | 6.15B | 1.13B | -421.00M |
| Depreciation & amortization | 674.00M | 682.00M | 697.00M | 722.00M | 650.00M | 655.00M |
| Free cash flow | 1.59B | -2.17B | 3.14B | 5.83B | 864.00M | -718.00M |
| Dividends paid | -412.00M | -401.00M | -402.00M | -396.00M | -417.00M | -409.00M |
| Stock buybacks / issuance | -1.44B | -1.04B | 37.00M | -976.00M | 57.00M | -179.00M |
| Ending cash balance | 8.38B | 4.39B | 6.07B | 7.74B | 7.08B | 6.36B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 9.63 | 11.82 | 17.68 | 11.01 | 14.50 | 11.34 | 7.87 | 14.40 |
| ROA %i | 2.45 | 3.30 | 5.44 | 3.46 | 4.46 | 3.48 | 2.23 | 3.80 |
| ROIC %i | 5.85 | 7.72 | 11.54 | 7.72 | 9.77 | 8.58 | 5.94 | 9.71 |
| 5-year avg ROE %i | 15.70 | 14.12 | 13.99 | 13.29 | 12.95 | 11.59 | 12.51 | 10.14 |
| EBIT margin %i | 8.40 | 5.42 | 7.73 | 4.63 | 5.34 | 3.59 | 2.72 | 3.36 |
| FCF / sales %i | 6.68 | 5.54 | 5.82 | 3.50 | 4.10 | 5.28 | 3.64 | 3.06 |
| Current ratioi | 0.64 | 0.74 | 0.77 | 0.83 | 0.73 | 0.77 | 0.84 | 0.85 |
| Quick ratioi | 0.51 | 0.41 | 0.66 | 0.48 | 0.58 | 0.54 | 0.56 | 0.67 |
| Debt / assetsi | 27.72 | 24.01 | 21.18 | 21.74 | 21.61 | 20.25 | 20.51 | 19.92 |
| LT debt / equityi | 96.33 | 70.35 | 58.71 | 66.07 | 62.90 | 60.91 | 70.52 | 74.01 |
| Interest coveragei | 8.19 | 4.91 | 8.56 | 6.61 | 7.80 | 4.81 | 4.67 | 6.53 |
| Revenue CAGR (3Y) %i | 7.59 | 56.10 | 57.70 | 54.07 | 5.63 | 6.84 | 12.58 | 15.15 |
| Net income CAGR (3Y) %i | 7.99 | 39.83 | 55.79 | 26.75 | 9.52 | -15.17 | -13.85 | -3.86 |
| FCF CAGR (3Y) %i | 10.19 | 33.25 | 36.81 | 23.03 | -4.44 | 3.43 | 14.05 | 4.45 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 12.37 | 12.31 | 14.65 | 14.40 | 15.26 | 15.49 |
| ROA %i | 3.31 | 3.27 | 3.90 | 3.80 | 4.14 | 4.16 |
| ROIC %i | 8.57 | 8.53 | 9.69 | 9.71 | 10.31 | 10.40 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 3.27 | 3.18 | 3.51 | 3.36 | 3.54 | 3.58 |
| FCF / sales %i | 2.36 | 1.51 | 2.78 | 3.06 | 2.77 | 3.24 |
| Current ratioi | 0.78 | 0.79 | 0.83 | 0.85 | 0.82 | 0.85 |
| Quick ratioi | 0.65 | 0.64 | 0.68 | 0.67 | 0.66 | 0.68 |
| Debt / assetsi | 20.21 | 20.29 | 21.56 | 19.92 | 20.16 | 20.29 |
| LT debt / equityi | 65.77 | 65.85 | 74.03 | 74.01 | 69.58 | 68.25 |
| Interest coveragei | 5.64 | 5.78 | 6.66 | 6.53 | 6.99 | 7.08 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Evernorth Health Services is the largest reported line at 85.77% of revenue, across 4 reported segments.
- The next-largest line, Cigna Healthcare, is a distant second at 16.52% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Evernorth Health Services85.77%
Cigna Healthcare16.52%
Other Operations0.18%
Quote time 2026-11-03 20:02:36 · For reference only, not investment advice and not tailored to your situation.
Cigna Group discussion 0 comments